BioSpace News Archive

With so much misinformation surrounding the draft National Coverage Determination (NCD) from the Centers for Medicare and Medicaid Services (CMS) not to cover the first class of Alzheimer’s drugs, except in very limited circumstances, UsAgainstAlzheimer’s is setting the record straight.

Liminal BioSciences Inc., provided an update in which it outlined key corporate and research and development priorities for 2022.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.

OSI Systems, Inc. announced that it will hold its quarterly conference call on Thursday, January 27, 2022 at 9:00am PT to discuss its results for the quarter ended December 31, 2021.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global interdental cleaning products market is expected to increase at a CAGR of 3% yearly through 2031, according to Fact.MR.

VYNE Therapeutics Inc. today announced that it has completed the Phase 1b portion of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD) (Study VY2021-01).

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that the Company and the Biomedical Advanced Research and Development Authority (BARDA) are expanding their existing partnership to develop tebipenem as a treatment for complicated urinary tract infections (cUTI).

Recce Pharmaceuticals Ltd is pleased to report further positive data from its Phase I intravenous (IV) clinical trial of RECCE® 327 (R327).

Obsidian Therapeutics, Inc. today announced that Maria Fardis , Ph.D., has assumed the role of Chair of Obsidian’s Board of Directors.

OnQuality Pharmaceuticals (“OnQuality”), today announced it will be presenting the results of an oncologist survey on willingness to use new medications to prevent or treat gastrointestinal side effects of cancer therapies in a poster at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).